Tenax Therapeutics Inc
TENX
Get informed when a big investor buys or sells
+ FollowMarket Cap$49.6M
Close$
$2.49
82.9% upside
Current Fair Value
82.9% upsideUndervalued by 82.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $49.60 Million |
|---|---|
| Enterprise Value | $-68,373,953.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.34 |
| Beta | 0.92 |
| Outstanding Shares | 50,869,259 |
Return
| Return on Equity | -57.10% |
|---|---|
| Return on Assets | -53.31% |
| Return on Invested Capital | 4.12% |
Valuation & Multiples
| P/E Ratio | -1.26 |
|---|---|
| PEG | -1.96 |
| Price to Sales | - |
| Price to Book Ratio | 0.68 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -14.6 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 18, 2026
EPS Estimate
$-0.40
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.35
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1831▲ 18.31% |
|---|---|
| Total Calls | 2,024,682▲ 1273.60% |
| Total Puts | 370,700▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 59.76%▲ 5.38% |
|---|---|
| Total Invested | $442.32M▲ 29.71% |
| Investors Holding | 129▲ 47.00% |
ESG Score
No data
About Tenax Therapeutics Inc
CEO: John Kelley